• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of FDA advisory committee member positions vacant at the end of the month

Dictionary: Access to state-of-the-art, scientific expert advice to support agency decision making processes is imperative to the FDA advisory committee process. Having the fewest vacancies on our committees allows the agency to have ready access to those experts and supports the ability of FDA to meet its public health mission. For more information about FDA advisory committees, please visit http://www.fda.gov/AdvisoryCommittees/default.htm

Information is current as of September 30, 2013.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetPercent Vacant Positions
Oct 20091033
Nov 20091036
Dec 200910TBD
Jan 201010TBD
Feb 20101035
Mar 20101036
Apr 20101034
May 20101033
Jun 20101031
Jul 20101035
Aug 20101029
Sep 20101026

Number of FDA advisory committee member positions vacant at the end of the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetVacant Positions
Oct 2009N/A199
Nov 2009N/A219
Dec 2009N/ATBD
Jan 2010N/ATBD
Feb 2010N/A213
Mar 2010N/A216
Apr 2010N/A209
May 2010N/A199
Jun 2010N/A189
Jul 2010N/A210
Aug 2010N/A177
Sep 2010N/A157

Total number of FDA advisory committee member positions at the end of the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetPositions
Oct 2009N/A608
Nov 2009N/A608
Dec 2009N/ATBD
Jan 2010N/ATBD
Feb 2010N/A608
Mar 2010N/A608
Apr 2010N/A608
May 2010N/A608
Jun 2010N/A608
Jul 2010N/A608
Aug 2010N/A608
Sep 2010N/A608

Footnotes

  • CVM's Advisory Committee was terminated on September 30, 2013.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.